SLC9A1 and acute myeloid leukemia: Our results indicate that NHE1 activity, rather than its total expression, may drive venetoclax resistance in certain AML subsets, explaining why resistant cells remain responsive to NHE1 inhibition despite lower NHE1 protein levels.